Alumnus Margaret McGlynn explains why New Yorkers should trust the COVID-19 vaccine

A leader in global vaccine development and distribution interviewed on COVID-19 vaccine development

By Kara Sweet

Published December 15, 2020

Margaret McGlynn, BS ’82 and MBA ’83, a global vaccine delivery expert, was recently featured in Buffalo Business First for her perspectives as an “educated bystander” on how the COVID-19 vaccine was developed so quickly and why we should feel safe and confident to receive the vaccine.

Margaret McGlynn.

McGlynn, along with a panel of other Western New York health care leaders, discussed the speed and success of vaccine development, including vaccine safety and efficacy. McGlynn explained how vaccine companies collaborated in response to the pandemic, and the importance of dynamic relationships between industry and academic laboratories for success.

Retired president for global vaccines and anti-infectives, Merck and Co., McGlynn has also advised global health efforts on the executive committee of the Global Alliance for Vaccine Immunization, a public private partnership focused on expanding access to new and under-used vaccines to the world’s most vulnerable children. 

For over 130 years, the University at Buffalo School of Pharmacy and Pharmaceutical Sciences has continually been a leader in the education of pharmacists and pharmaceutical scientists, renowned for innovation in clinical practice and research. The school is accredited by the American Council of Pharmaceutical Education (ACPE) and is the No. 1 ranked school of pharmacy in New York State and No. 14 in the United States by U.S. News & World Report.